JP2020526485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526485A5 JP2020526485A5 JP2019571280A JP2019571280A JP2020526485A5 JP 2020526485 A5 JP2020526485 A5 JP 2020526485A5 JP 2019571280 A JP2019571280 A JP 2019571280A JP 2019571280 A JP2019571280 A JP 2019571280A JP 2020526485 A5 JP2020526485 A5 JP 2020526485A5
- Authority
- JP
- Japan
- Prior art keywords
- substance according
- propionic acid
- butyric acid
- substance
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 30
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 19
- 235000019260 propionic acid Nutrition 0.000 claims description 15
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 230000003319 supportive effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017115819.7A DE102017115819A1 (de) | 2017-07-13 | 2017-07-13 | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| DE102017115819.7 | 2017-07-13 | ||
| PCT/EP2018/069089 WO2019012108A1 (de) | 2017-07-13 | 2018-07-13 | Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526485A JP2020526485A (ja) | 2020-08-31 |
| JP2020526485A5 true JP2020526485A5 (enExample) | 2021-02-04 |
| JP7206223B2 JP7206223B2 (ja) | 2023-01-17 |
Family
ID=63108510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571280A Active JP7206223B2 (ja) | 2017-07-13 | 2018-07-13 | パーキンソン病の予防および／または支持治療処置のための物質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200163914A1 (enExample) |
| EP (1) | EP3651754B1 (enExample) |
| JP (1) | JP7206223B2 (enExample) |
| KR (1) | KR20200027976A (enExample) |
| CN (1) | CN110996933A (enExample) |
| AU (2) | AU2018298862A1 (enExample) |
| BR (1) | BR112020000570A2 (enExample) |
| CA (1) | CA3067728A1 (enExample) |
| DE (1) | DE102017115819A1 (enExample) |
| WO (1) | WO2019012108A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021048440A1 (en) | 2019-09-13 | 2021-03-18 | Basf Se | Composition for the treatment of neurodegenerative diseases |
| CN111450238A (zh) * | 2020-03-31 | 2020-07-28 | 上海交通大学医学院附属瑞金医院 | 骨钙素或丙酸在制备抗帕金森病药物中的应用 |
| CN113332266A (zh) * | 2021-06-10 | 2021-09-03 | 徐州医科大学 | 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19503598A1 (de) * | 1995-02-03 | 1996-08-08 | Zuzana Dr Cully | Verfahren zur fermentativen Herstellung von Propionsäure oder Buttersäure bzw. deren Salze |
| NL1009990C2 (nl) * | 1998-09-02 | 2000-03-15 | Sibeco Chemicals | Voedingssupplement en werkwijze voor het vervaardigen van zulk voedingssupplement. |
| US20060105962A1 (en) * | 2004-11-14 | 2006-05-18 | Robinson Robert O A | Tonic to maintain intestinal flora |
| RU2578391C2 (ru) * | 2011-01-12 | 2016-03-27 | Альберт ДАКСЕР | Напиток |
| US9764019B2 (en) * | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| CN105055457A (zh) * | 2015-08-06 | 2015-11-18 | 温州医科大学附属第二医院 | 一种防治阿尔茨海默病的药物及其制备方法和应用 |
| DE102016103242A1 (de) * | 2016-02-24 | 2017-08-24 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur unterstützenden Immunmodulation |
| WO2017091072A1 (en) * | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
| CN110475551A (zh) * | 2017-01-27 | 2019-11-19 | 英联邦高等教育系统天普大学 | 使用短链脂肪酸治疗和预防疾病和障碍 |
-
2017
- 2017-07-13 DE DE102017115819.7A patent/DE102017115819A1/de not_active Withdrawn
-
2018
- 2018-07-13 BR BR112020000570-3A patent/BR112020000570A2/pt not_active Application Discontinuation
- 2018-07-13 US US16/627,688 patent/US20200163914A1/en not_active Abandoned
- 2018-07-13 CA CA3067728A patent/CA3067728A1/en active Pending
- 2018-07-13 WO PCT/EP2018/069089 patent/WO2019012108A1/de not_active Ceased
- 2018-07-13 JP JP2019571280A patent/JP7206223B2/ja active Active
- 2018-07-13 KR KR1020207003431A patent/KR20200027976A/ko not_active Ceased
- 2018-07-13 EP EP18750103.6A patent/EP3651754B1/de active Active
- 2018-07-13 CN CN201880042374.6A patent/CN110996933A/zh active Pending
- 2018-07-13 AU AU2018298862A patent/AU2018298862A1/en not_active Abandoned
-
2021
- 2021-11-26 AU AU2021273627A patent/AU2021273627B2/en active Active
-
2022
- 2022-06-20 US US17/807,797 patent/US20220313634A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2710540T5 (es) | Preparación de compuesto de ácido graso omega-3 | |
| JP2009525985A5 (enExample) | ||
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| NO328797B1 (no) | Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt. | |
| JP2015524444A5 (enExample) | ||
| JP2016053065A5 (enExample) | ||
| HRP20240115T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
| ES2567595T3 (es) | Métodos y artículos para tratar la insuficiencia y la deficiencia de 25-hidroxivitamina D | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| ES2640816T3 (es) | Utilización de una matriz para administración oral de magnesio de liberación prolongada y composición que contiene esta matriz | |
| RU2020101477A (ru) | Фармацевтические композиции, содержащие дглк, и их применение | |
| JP2005528430A5 (enExample) | ||
| JP2013544290A5 (enExample) | ||
| JP2019504024A (ja) | 腎結石を治療する医薬製剤ならびにその製造方法および用法 | |
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| JP7206223B2 (ja) | パーキンソン病の予防および／または支持治療処置のための物質 | |
| JP2008537734A (ja) | 経口で用いられる適合溶質を含む薬剤 | |
| RS59303B1 (sr) | Spojnica | |
| JP2012041314A5 (enExample) | ||
| US20070299127A1 (en) | Compositions and kits comprising a melatonin component and an omega-3-fatty acid component | |
| CA2294095C (en) | Synergistically acting compositions for selectively combating tumor tissue | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| RU2016144695A (ru) | Комплекс танната ситаглиптина | |
| ES2422877A2 (es) | Combinación y composición para el tratamiento de obesidad |